Getting paid: Use a side-by-side comparison of drug screen policies to avoid denials

Why This Topic Matters

Urine drug testing claims are highly policy-driven, and payer-specific differences can lead to denials if they are not tracked carefully. Understanding the general landscape helps practices align documentation, coverage checks, and claim submission with each payer’s requirements.

Article Sections

1. National Government Services is heavy on detail

   This section summarizes the Medicare contractor’s detailed urine drug testing policy and the kinds of guidance it includes. It covers terminology, testing methods, specimen considerations, panel use, covered indications, and related policy elements.

2. Anthem won’t allow unbundling

   This section compares Anthem’s policy approach, including bundling treatment, documentation expectations, frequency limits, and covered testing categories. It also notes tools and other policy features included in the plan guidance.

3. Cigna limits definitive drug tests

   This section outlines Cigna’s general approach to urine drug testing, including frequency guidance, plan-wide coverage notes, effective dates, definition emphasis, and bundling-related policy points. It highlights that the carrier’s guidance is tied to its transition to newer drug testing policies.

4. Private payers continue to shift

   This brief closing section describes the broader trend among commercial payers adopting newer urine drug screen policies. It notes that policy implementation dates may differ from code effective dates.